$NRXP
NRX Pharmaceuticals, Inc.

2024 Q1 Form 10-K Financial Statement

#000155837024004396 Filed on March 29, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.250M $1.872M $14.22M
YoY Change -26.53% -65.54% -47.94%
% of Gross Profit
Research & Development $1.748M $2.534M $13.37M
YoY Change -52.11% -43.13% -21.47%
% of Gross Profit
Depreciation & Amortization $1.000K $1.000K $5.000K
YoY Change 0.0% 0.0% 25.0%
% of Gross Profit
Operating Expenses $5.998M $4.406M $27.59M
YoY Change -36.43% -55.44% -37.78%
Operating Profit -$5.998M -$27.84M
YoY Change -36.43% -37.21%
Interest Expense $230.0K -$6.000K $374.0K
YoY Change 36.9% -103.95% -25.79%
% of Operating Profit
Other Income/Expense, Net -$530.0K $80.00K -$2.687M
YoY Change -66.96% -115.84% -158.66%
Pretax Income -$6.528M -$4.332M -$30.15M
YoY Change -40.86% -57.7% -24.16%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$6.528M -$4.341M -$30.16M
YoY Change -40.86% -57.61% -24.14%
Net Earnings / Revenue
Basic Earnings Per Share -$0.74 -$0.40
Diluted Earnings Per Share -$0.74 -$0.05 -$0.40
COMMON SHARES
Basic Shares Outstanding 95.70M 83.92M 75.76M
Diluted Shares Outstanding 8.852M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.319M $4.595M $4.595M
YoY Change -92.01% -77.09% -77.09%
Cash & Equivalents $1.319M $4.595M
Short-Term Investments
Other Short-Term Assets $128.0K $2.289M $2.289M
YoY Change -97.56% -60.13% -60.13%
Inventory
Prepaid Expenses
Receivables
Other Receivables $6.000K
Total Short-Term Assets $3.347M $6.884M $6.884M
YoY Change -84.62% -73.31% -73.31%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $441.0K $431.0K $431.0K
YoY Change 1737.5% 1952.38% 1952.38%
Total Long-Term Assets $441.0K $431.0K $431.0K
YoY Change 1737.5% 1952.38% 1952.38%
TOTAL ASSETS
Total Short-Term Assets $3.347M $6.884M $6.884M
Total Long-Term Assets $441.0K $431.0K $431.0K
Total Assets $3.788M $7.315M $7.315M
YoY Change -82.61% -71.66% -71.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.265M $4.632M $4.632M
YoY Change 65.92% 123.12% 123.12%
Accrued Expenses $5.296M $4.633M $4.633M
YoY Change 4.79% -4.57% 2.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $6.779M $9.161M $9.161M
YoY Change -44.38% 18.93% 18.93%
Total Short-Term Liabilities $18.86M $19.05M $19.05M
YoY Change -14.53% 22.22% 22.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.86M $19.05M $19.05M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $18.86M $19.05M $19.05M
YoY Change -14.53% 3.48% 3.48%
SHAREHOLDERS EQUITY
Retained Earnings -$259.7M -$253.1M
YoY Change 10.96% 13.52%
Common Stock $10.00K $84.00K
YoY Change -85.71% 25.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$15.07M -$11.73M -$11.73M
YoY Change
Total Liabilities & Shareholders Equity $3.788M $7.315M $7.315M
YoY Change -82.61% -71.66% -71.66%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$6.528M -$4.341M -$30.16M
YoY Change -40.86% -57.61% -24.14%
Depreciation, Depletion And Amortization $1.000K $1.000K $5.000K
YoY Change 0.0% 0.0% 25.0%
Cash From Operating Activities -$3.671M -$3.192M -$21.66M
YoY Change -39.71% -61.63% -45.52%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$1.000K $3.000K
YoY Change -100.0% 0.0% -70.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $1.000K -$3.000K
YoY Change -100.0% 0.0% -70.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.293M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 395.0K -1.116M 6.201M
YoY Change -84.48% -111.03% -80.75%
NET CHANGE
Cash From Operating Activities -3.671M -3.192M -21.66M
Cash From Investing Activities 0.000 1.000K -3.000K
Cash From Financing Activities 395.0K -1.116M 6.201M
Net Change In Cash -3.276M -4.307M -15.46M
YoY Change -7.67% -338.61% 104.73%
FREE CASH FLOW
Cash From Operating Activities -$3.671M -$3.192M -$21.66M
Capital Expenditures $0.00 -$1.000K $3.000K
Free Cash Flow -$3.671M -$3.191M -$21.66M
YoY Change -39.75% -61.63% -45.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001719406
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Registrant Name
EntityRegistrantName
NRX Pharmaceuticals, Inc.
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83919554
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66442989
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-38302
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2844431
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
1201 Orange Street
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Wilmington
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
DE
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19801
CY2023 dei City Area Code
CityAreaCode
484
CY2023 dei Local Phone Number
LocalPhoneNumber
254-6134
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
29700000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
95699780
CY2023 dei Auditor Firm
AuditorFirmId
185
CY2023 dei Auditor Name
AuditorName
Salberg & Company, P.A
CY2023 dei Auditor Location
AuditorLocation
Boca Raton, Florida
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4595000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20054000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2289000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5741000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
6884000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
25795000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
431000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21000
CY2023Q4 us-gaap Assets
Assets
7315000
CY2022Q4 us-gaap Assets
Assets
25816000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4632000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2076000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4714000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4855000
CY2023Q4 nrxp Accrued Clinical Site Costs
AccruedClinicalSiteCosts
524000
CY2022Q4 nrxp Accrued Clinical Site Costs
AccruedClinicalSiteCosts
914000
CY2023Q4 nrxp Convertible Notes Payable Accrued Interest
ConvertibleNotesPayableAccruedInterest
9161000
CY2022Q4 nrxp Convertible Notes Payable Accrued Interest
ConvertibleNotesPayableAccruedInterest
7703000
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
17000
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
37000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19048000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15585000
CY2022Q4 nrxp Notes Payable And Accrued Interest Non Current
NotesPayableAndAccruedInterestNonCurrent
2822000
CY2023Q4 us-gaap Liabilities
Liabilities
19048000
CY2022Q4 us-gaap Liabilities
Liabilities
18407000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83919554
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66442989
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
84000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
67000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
241330000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
230339000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-253147000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-222997000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-11733000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7409000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7315000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25816000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13371000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17027000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14216000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27308000
CY2023 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
250000
CY2023 us-gaap Operating Expenses
OperatingExpenses
27837000
CY2022 us-gaap Operating Expenses
OperatingExpenses
44335000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-27837000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-44335000
CY2023 us-gaap Interest Income Other
InterestIncomeOther
494000
CY2022 us-gaap Interest Income Other
InterestIncomeOther
249000
CY2023 us-gaap Interest Expense
InterestExpense
120000
CY2023 nrxp Increase Decrease In Fair Value Of Convertible Debt
IncreaseDecreaseInFairValueOfConvertibleDebt
-2707000
CY2022 nrxp Increase Decrease In Fair Value Of Convertible Debt
IncreaseDecreaseInFairValueOfConvertibleDebt
-505000
CY2023 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
20000
CY2022 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
255000
CY2022 nrxp Gain Loss On Fair Value Of Cash Earnout Liability
GainLossOnFairValueOfCashEarnoutLiability
4582000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2313000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4581000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-30150000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-39754000
CY2023 nrxp Deemed Dividend Warrants
DeemedDividendWarrants
9000
CY2023 nrxp Net Loss Attributable To Common Stockholders
NetLossAttributableToCommonStockholders
-30159000
CY2022 nrxp Net Loss Attributable To Common Stockholders
NetLossAttributableToCommonStockholders
-39754000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-30150000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-39754000
CY2023 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option Reclassification Adjustment From Aoci For Derecognition After Tax
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax
-3000
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
30153000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
39754000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75761763
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65766786
CY2023 us-gaap Profit Loss
ProfitLoss
-30150000
CY2022 us-gaap Profit Loss
ProfitLoss
-39754000
CY2023 us-gaap Depreciation
Depreciation
5000
CY2022 us-gaap Depreciation
Depreciation
4000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
387000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
3628000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-20000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-255000
CY2022 nrxp Gain Loss On Fair Value Of Cash Earnout Liability
GainLossOnFairValueOfCashEarnoutLiability
4582000
CY2023 nrxp Increase Decrease In Fair Value Of Convertible Debt
IncreaseDecreaseInFairValueOfConvertibleDebt
-2707000
CY2022 nrxp Increase Decrease In Fair Value Of Convertible Debt
IncreaseDecreaseInFairValueOfConvertibleDebt
-505000
CY2023 nrxp Noncash Settlement Expense
NoncashSettlementExpense
250000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3040000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
632000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2655000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1611000
CY2023 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-531000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2942000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21657000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39755000
CY2023 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
3000
CY2022 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
10000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10000
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
10020000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10000
CY2022 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-518000
CY2023 nrxp Repayments Of Convertible Note
RepaymentsOfConvertibleNote
3092000
CY2023 nrxp Repayments Of Insurance Loan
RepaymentsOfInsuranceLoan
943000
CY2023 nrxp Proceeds From Issuance Of Insurance Loan
ProceedsFromIssuanceOfInsuranceLoan
943000
CY2023 us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
1171000
CY2023 nrxp Net Proceeds From Payments For Issuance Of Common Stock And Warrants In Private Placement Net Of Issuance Costs
NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts
8122000
CY2022 nrxp Net Proceeds From Payments For Issuance Of Common Stock And Warrants In Private Placement Net Of Issuance Costs
NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts
22702000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6201000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32214000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-15459000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7551000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20054000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27605000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4595000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20054000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
885000
CY2023 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
982000
CY2023 nrxp Issuance Of Common Stock Warrants As Offering Costs
IssuanceOfCommonStockWarrantsAsOfferingCosts
75000
CY2022 nrxp Issuance Of Common Stock Warrants As Offering Costs
IssuanceOfCommonStockWarrantsAsOfferingCosts
726000
CY2023 us-gaap Stock Issued1
StockIssued1
250000
CY2023Q4 us-gaap Cash
Cash
4600000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The preparation of consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s consolidated financial statements relate to the fair value of the convertible note payable, earnout cash liability, fair value of stock options and warrants, and the utilization of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. </p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk and Off-Balance Sheet Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Deposits in financial institutions may, from time to time, exceed federally insured limits. As of December 31, 2023 the Company’s cash and cash equivalents balance within money market accounts was in excess of the U.S. federally insured limits by $4.1 million. The Company has not experienced any losses on its deposits of cash. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy.  </p>
CY2023Q4 nrxp Prepaid Clinical Development Expenses
PrepaidClinicalDevelopmentExpenses
1078000
CY2022Q4 nrxp Prepaid Clinical Development Expenses
PrepaidClinicalDevelopmentExpenses
3167000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
871000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1966000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
334000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
331000
CY2023Q4 nrxp Prepaid Legal Expenses
PrepaidLegalExpenses
6000
CY2022Q4 nrxp Prepaid Legal Expenses
PrepaidLegalExpenses
7000
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
270000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2289000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5741000
CY2023Q4 nrxp Other Accrued Expenses Current
OtherAccruedExpensesCurrent
2686000
CY2022Q4 nrxp Other Accrued Expenses Current
OtherAccruedExpensesCurrent
342000
CY2023Q4 nrxp Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1112000
CY2022Q4 nrxp Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
974000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
835000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
923000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
81000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2616000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4714000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4855000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
11020000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
11020000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
497000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1000000
CY2023Q4 nrxp Debt Instrument Repayments Of Principal
DebtInstrumentRepaymentsOfPrincipal
4072000
CY2023Q4 nrxp Long Term Debt Before Fair Value Adjustments
LongTermDebtBeforeFairValueAdjustments
6451000
CY2022Q4 nrxp Long Term Debt Before Fair Value Adjustments
LongTermDebtBeforeFairValueAdjustments
10020000
CY2023 nrxp Increase Decrease In Fair Value Of Convertible Debt
IncreaseDecreaseInFairValueOfConvertibleDebt
-2707000
CY2022 nrxp Increase Decrease In Fair Value Of Convertible Debt
IncreaseDecreaseInFairValueOfConvertibleDebt
-505000
CY2023 nrxp Increase Decrease In Fair Value Accumulated Other Comprehensive Income
IncreaseDecreaseInFairValueAccumulatedOtherComprehensiveIncome
3000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
9161000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
10525000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
9161000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7703000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2822000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022 nrxp Common Stock And Warrants Issued In Private Placement Number Of Shares
CommonStockAndWarrantsIssuedInPrivatePlacementNumberOfShares
7824727
CY2022 nrxp Net Proceeds From Payments For Issuance Of Common Stock And Warrants In Private Placement Net Of Issuance Costs
NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts
22700000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.503
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2548849
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.20
CY2022 nrxp Share Based Compensation Arrangement Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y2M12D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2549000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
900000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.64
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
790021
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.28
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2649828
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.83
CY2023 nrxp Share Based Compensation Arrangement Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
75000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1511323
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
2.31
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y4M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
42000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
300000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y3M18D
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.0018
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.0008
CY2022 nrxp Effective Income Tax Rate Reconciliation Fair Market Value Earnout
EffectiveIncomeTaxRateReconciliationFairMarketValueEarnout
0.0242
CY2023 nrxp Effective Income Tax Rate Reconciliation Settlement Warrants
EffectiveIncomeTaxRateReconciliationSettlementWarrants
-0.0002
CY2022 nrxp Effective Income Tax Rate Reconciliation Settlement Warrants
EffectiveIncomeTaxRateReconciliationSettlementWarrants
0.0000
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0321
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.0001
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.0033
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0474
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0162
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.0945
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.2464
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.0166
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0011
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-4278000
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-9295000
CY2022 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
133000
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
1428000
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-647000
CY2023 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
2850000
CY2022 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
9809000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
35860000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
33640000
CY2023Q4 nrxp Deferred Tax Assets Common Stock Warrants
DeferredTaxAssetsCommonStockWarrants
1822000
CY2022Q4 nrxp Deferred Tax Assets Common Stock Warrants
DeferredTaxAssetsCommonStockWarrants
1894000
CY2023Q4 nrxp Deferred Tax Assets174 Capitalization
DeferredTaxAssets174Capitalization
5169000
CY2022Q4 nrxp Deferred Tax Assets174 Capitalization
DeferredTaxAssets174Capitalization
3410000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1400000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2411000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
167000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
202000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
488000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
500000
CY2023Q4 nrxp Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
2000
CY2022Q4 nrxp Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
3000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
44904000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
42054000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
44904000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42054000
CY2022Q4 nrxp Minimum Equity Value Required For Transfer Of Assets
MinimumEquityValueRequiredForTransferOfAssets
50000000
CY2022Q4 nrxp Minimum Equity Required For Transfer Of Assets From Related Party Number Of Consecutive Trading Days
MinimumEquityRequiredForTransferOfAssetsFromRelatedPartyNumberOfConsecutiveTradingDays
20
CY2022Q4 nrxp Minimum Equity Required For Transfer Of Assets From Related Party Number Of Trading Days
MinimumEquityRequiredForTransferOfAssetsFromRelatedPartyNumberOfTradingDays
20
CY2023Q1 nrxp License Agreement Threshold Aggregate Liquidity
LicenseAgreementThresholdAggregateLiquidity
600000
CY2023Q1 nrxp Related Party Transaction Consulting Fee Payable Per Month
RelatedPartyTransactionConsultingFeePayablePerMonth
100000
CY2023Q1 nrxp Related Party Transactions Performance Based Annual Bonus Minimum Target
RelatedPartyTransactionsPerformanceBasedAnnualBonusMinimumTarget
300000
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-004396-index-headers.html Edgar Link pending
0001558370-24-004396-index.html Edgar Link pending
0001558370-24-004396.txt Edgar Link pending
0001558370-24-004396-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nrxp-20231231.xsd Edgar Link pending
nrxp-20231231x10k.htm Edgar Link pending
nrxp-20231231x10k001.jpg Edgar Link pending
nrxp-20231231x10k002.jpg Edgar Link pending
nrxp-20231231x10k003.jpg Edgar Link pending
nrxp-20231231x10k004.jpg Edgar Link pending
nrxp-20231231x10k005.jpg Edgar Link pending
nrxp-20231231x10k006.jpg Edgar Link pending
nrxp-20231231x10k007.jpg Edgar Link pending
nrxp-20231231x10k008.jpg Edgar Link pending
nrxp-20231231x10k009.jpg Edgar Link pending
nrxp-20231231x10k010.jpg Edgar Link pending
nrxp-20231231x10k011.jpg Edgar Link pending
nrxp-20231231x10k012.jpg Edgar Link pending
nrxp-20231231xex10d55.htm Edgar Link pending
nrxp-20231231xex10d60.htm Edgar Link pending
nrxp-20231231xex10d64.htm Edgar Link pending
nrxp-20231231xex10d66.htm Edgar Link pending
nrxp-20231231xex23d1.htm Edgar Link pending
nrxp-20231231xex31d1.htm Edgar Link pending
nrxp-20231231xex31d2.htm Edgar Link pending
nrxp-20231231xex32d1.htm Edgar Link pending
nrxp-20231231xex32d2.htm Edgar Link pending
nrxp-20231231xex4d8.htm Edgar Link pending
nrxp-20231231xex4d9.htm Edgar Link pending
nrxp-20231231xex97d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nrxp-20231231_cal.xml Edgar Link unprocessable
nrxp-20231231_def.xml Edgar Link unprocessable
nrxp-20231231_lab.xml Edgar Link unprocessable
nrxp-20231231_pre.xml Edgar Link unprocessable
nrxp-20231231x10k_htm.xml Edgar Link completed
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending